Podcasts about Avera

In this episode, Thomas Otten, Vice President of Avera Behavioral Health Services, discusses Avera's innovative approach to behavioral health, including the expansion of inpatient services, the launch of an urgent care model, and future initiatives like psychiatric residential treatment for adolescents.

In this episode, Thomas Otten, Vice President of Avera Behavioral Health Services, discusses Avera's innovative approach to behavioral health, including the expansion of inpatient services, the launch of an urgent care model, and future initiatives like psychiatric residential treatment for adolescents.

Martin berichtet über die Teilnahme an der Session von Jochen Robes: gemeinsam als Community wollen wir ein Buch über die Entwicklung, die verschiedenen Aktionen und Formate und vor allem die Energie der Corporate Learning Community schreiben. Julia, Sebastian und Karlheinz berichten über die Session von Herweg Kummer, in der das AVERA-Modell der Corporate Learning Community Austria anhand von Praxisbeispielen vorgestellt wurde. Die Kernbotschaft lautet: für erfolgreiche Lern- und Veränderungsinitiativen sind immer das Business und das Corporate Learning gemeinsam verantwortlich.  Henning berichtet von seiner Session zu den Ergebnissen der Zukunftskonferenzen der Corporate Learning Community. Seine Kernbotschaft: wir müssen als CLC noch sichtbarer werden, um auch jüngere Learning Professionals noch mehr für uns zu begeistern! Der hybride Gesprächstisch ist ein Podcast-Tisch, der beim Camp von insgesamt 15 Community-Mitgliedern im stündlichen Wechsel moderiert wurde.

In this episode, Julie Lautt, CFO of Avera Health, shares insights on the healthcare industry's evolving financial landscape. She discusses key trends, policy impacts, and Avera's ambitious growth strategy—including major capital investments and service expansions—to enhance patient care across five states.

In this episode of 'The Move,' host Larry Williams engages in a compelling conversation with Lindsey Meyers from Avera Health. They discuss the critical issue of suicide prevention and the rapid decision-making that can lead to suicide. Lindsey delves into Avera's proactive strategies, including their impactful 'Ask the Question' campaign, which encourages the public to directly ask their loved ones about suicidal thoughts. She shares her extensive experience in communications and behavioral health marketing, highlighting the collaborative efforts within Avera to tackle mental health challenges. The episode emphasizes the importance of storytelling, social media, and community partnerships in breaking the stigma around mental health and improving access to services. Lindsey also touches on the future of mental health marketing, including the role of artificial intelligence and workforce development in rural areas. A must-listen for those interested in the intersection of healthcare, marketing, and mental health advocacy.   00:00 Introduction to Suicide Prevention 01:17 The Role of Healthcare Systems in Mental Health 01:34 Meet Lindsey Meyers from Avera Health 02:52 Lindsey's Journey in Behavioral Health Marketing 05:34 Avera's Proactive Approach to Mental Health 09:59 Impact of COVID-19 on Mental Health Services 12:19 Ask the Question Campaign 17:53 Communication Challenges in Mental Health 25:27 Storytelling and Social Media in Healthcare 31:19 Future Trends in Mental Health Marketing 33:18 Avera Health's Future Goals 35:23 Conclusion and Contact Information Learn more about your ad choices. Visit megaphone.fm/adchoices

Bajo la brillante fachada de la alta sociedad de Nueva Orleans acechaba una oscuridad que desafiaba la imaginación. Delphine LaLaurie, guardaba un secreto escalofriante dentro de las paredes de su elegante mansión. Detrás de las opulentas fiestas, LaLaurie sometía a sus esclavos a horrores indescriptibles, transformando su hogar en una casa de tormento. Cuando un incendio expuso sus horribles crímenes, la ciudad estalló en indignación, revelando la monstruosa verdad oculta tras la cautivadora personalidad de LaLaurie y grabando para siempre su nombre en la infamia. También puedes escucharnos en Spotify, Apple Podcasts, Amazon Music o tu app de podcasts favorita. Apóyanos en Patreon: https://www.patreon.com/leyendaspodcast Apóyanos en YouTube: https://www.youtube.com/c/leyendaslegendarias/join Visita nuestra página para ver contenido extra: www.leyendaslegendarias.com Síguenos: https://instagram.com/leyendaspodcast https://twitter.com/leyendaspodcast https://facebook.com/leyendaspodcast #Podcast #LeyendasLegendarias Learn more about your ad choices. Visit megaphone.fm/adchoices

Bajo la brillante fachada de la alta sociedad de Nueva Orleans acechaba una oscuridad que desafiaba la imaginación. Delphine LaLaurie, guardaba un secreto escalofriante dentro de las paredes de su elegante mansión. Detrás de las opulentas fiestas, LaLaurie sometía a sus esclavos a horrores indescriptibles, transformando su hogar en una casa de tormento. Cuando un incendio expuso sus horribles crímenes, la ciudad estalló en indignación, revelando la monstruosa verdad oculta tras la cautivadora personalidad de LaLaurie y grabando para siempre su nombre en la infamia. También puedes escucharnos en Spotify, Apple Podcasts, Amazon Music o tu app de podcasts favorita. Apóyanos en Patreon: https://www.patreon.com/leyendaspodcast Apóyanos en YouTube: https://www.youtube.com/c/leyendaslegendarias/join Visita nuestra página para ver contenido extra: www.leyendaslegendarias.com Síguenos: https://instagram.com/leyendaspodcast https://twitter.com/leyendaspodcast https://facebook.com/leyendaspodcast #Podcast #LeyendasLegendarias Learn more about your ad choices. Visit megaphone.fm/adchoices

Em 7 de setembro de 2014, um jovem negro saiu de casa e nunca mais voltou. Ele atravessou uma das fronteiras mais vigiadas do mundo e desapareceu. Por dez anos, sua família esperou, lutou e clamou por respostas. Até que, em 2025, um cessar-fogo trouxe esperança.Hoje, nosso episódio é um pouco diferente: em vez de uma entrevista, vamos contar a história de Avera Mengistu. Um jovem negro, africano,  judeu e cidadão israelense, que passou para o outro lado do muro, entrando na Faixa de Gaza e foi esquecido por muitos anos.

In this episode Drew & Fuse sit down to talk with DJ Avera from New Jersey. They her success on YouTube. Working with a booking agency, top music picks. Tune in and give it a listen! We appreciate all you that listen & Watch. We like hearing from you all, give us a theme for the next music episode if you'd like! As always please like, share, follow, rate, review, download, and all that good stuff to help grow the show. Use coupon code “DrewAndFuseShow" at https://www.directmusicservice.com for 30% off your first month of activation. Use coupon code ''DAFS" at https://www.cratehackers.com to get 50% off your first 3 months or 30% off the annual plan! Use promo code "DAFS" at Briggs Beard Co. for 20% off! https://briggsbeardco.com/ Get $25 off any #ClubCannon Product over $250 using this link: https://www.clubcannon.com/coupon/dafs #djs #serato #podcast #musicpodcast #djpodcast #djing #djtalk

In this episode, we explore the innovative group purchasing program offered by Avera PACE, a solution designed to help organizations reduce costs and improve efficiency. Our guest, Kevin Jordanger, Director, dives into how the program leverages collective buying power to secure competitive pricing on essential supplies and services.Learn how this initiative supports businesses of all sizes and drives operational savings. Whether you're managing a healthcare facility, a corporate office or a small business this conversation offers valuable insights and savings opportunities.https://www.avera.org/pace/

In this episode we hear from a Clinical Program Manager about the inception, operation, and impact of The Link, a community triage center in Sioux Falls, South Dakota. Learn how it was born out of a data-driven need for enhanced mental health and substance use services, and the collaborative efforts with community stakeholders, hospitals, and law enforcement that brought it to life. The episode delves into how the center combats stigma, addresses health equity, and provides culturally sensitive care, particularly to the American Indian population. Hear about the operational challenges, successes, and future vision for the center, highlighting how healthcare IT and data have played crucial roles in their ongoing efforts to improve community health outcomes. Practical insights and inspiration are offered for those looking to replicate or support similar initiatives in their own communities. HOST Janet Desroche Associate VP, MEDITECH    GUEST Kelsey Sjaarda, MSW, CSW-PIP Clinical Program Manager, Avera Behavioral Health and The Link Kelsey Sjaarda, MSW, CSW-PIP, has been with Avera for over 12 years and oversees their partial hospitalization program as well as operations of The Link. Kelsey earned her Master of Social Work at the Mankato campus of Minnesota State University.   What you'll learn about: Origins and purpose of The Link, a community triage center addressing mental health and substance use in Sioux Falls, SD. Data-Driven Research & Planning such as leveraging the data from the Community Health Needs Assessment (CHNA) to justify and establish the center. Insights into operational challenges and milestones The role of Healthcare IT and data in improving and streamlining services at the center. Importance of collaborative efforts and partnerships with local hospitals, emergency departments, law enforcement, and community stakeholders in creating the center. How the center is addressing stigma and providing cultural sensitivity training for their staff, especially in serving the American Indian population and addressing health equity disparities. Programs and Services the center offers including: sobering services, medical withdrawal management, and the referral process for ongoing care. Impact and Outcomes: Evidence of improvements and success measures based on collected data, including patient and community feedback. Vision for the Future: Future goals and aspirations for The Link, including seeking alternative funding and expanding their blueprint to other communities. Community Stories and Successes: Real-life stories of patients and the community impact of The Link's services.

A Monday morning explosion in O'Neill Nebraska destroyed the St. Patrick's Parish Center and damaged a nearby school and hospital. There are no injuries reported, but patients at Avera (uh-VAIR-uh) Saint Anthony's Hospital were evacuated to another hospital and classes were canceled at St. Mary's Grade School and High School. An investigation from the Nebraska State Patrol and Nebraska State Fire Marshal's office is ongoing into the cause of the explosion.

A Monday morning explosion in O'Neill Nebraska destroyed the St. Patrick's Parish Center and damaged a nearby school and hospital. There are no injuries reported, but patients at Avera (uh-VAIR-uh) Saint Anthony's Hospital were evacuated to another hospital and classes were canceled at St. Mary's Grade School and High School. An investigation from the Nebraska State Patrol and Nebraska State Fire Marshal's office is ongoing into the cause of the explosion.

A Monday morning explosion in O'Neill Nebraska destroyed the St. Patrick's Parish Center and damaged a nearby school and hospital. There are no injuries reported, but patients at Avera (uh-VAIR-uh) Saint Anthony's Hospital were evacuated to another hospital and classes were canceled at St. Mary's Grade School and High School. An investigation from the Nebraska State Patrol and Nebraska State Fire Marshal's office is ongoing into the cause of the explosion.

A Monday morning explosion in O'Neill Nebraska destroyed the St. Patrick's Parish Center and damaged a nearby school and hospital. There are no injuries reported, but patients at Avera (uh-VAIR-uh) Saint Anthony's Hospital were evacuated to another hospital and classes were canceled at St. Mary's Grade School and High School. An investigation from the Nebraska State Patrol and Nebraska State Fire Marshal's office is ongoing into the cause of the explosion.

September is National Suicide Prevention Month and for the third year, Avera Health launched its ‘Ask The Question' campaign. This campaign is built around the research-based premise that being direct can save lives. Asking someone who's struggling a direct question, “Are you thinking about suicide?” in a caring way can open a meaningful conversation that leads to the person at risk to get help. It's not always an easy conversation to have. But on the bright side: Suicide rates have fallen in South Dakota for two years in a row. To tell us more about what programs Avera offers for the community and events involving starting a conversation, Thomas Otten the Vice President of Avera Behavioral Health joins the program. More information can be found at avera.org/askthequestion.

¿Estás listx para saciar tu sed de misterio? Toma tu pala, tu cinta aislante y tu cuchillo preferido, ¡porque en Leyendas Legendarias desenterramos a tus asesinos seriales favoritos! La historia de un productor musical que reclutaba niñas con la ayuda de una cantante. Les prometía llevarlas al éxito en la música, pero en realidad sólo las quería para abusar sexualmente de ellas. También puedes escucharnos en Spotify, Apple Podcasts, Amazon Music o tu app de podcasts favorita. Apóyanos en Patreon: https://www.patreon.com/leyendaspodcast Apóyanos en YouTube: https://www.youtube.com/c/leyendaslegendarias/join Visita nuestra página para ver contenido extra: www.leyendaslegendarias.com Síguenos: https://instagram.com/leyendaspodcast https://twitter.com/leyendaspodcast https://facebook.com/leyendaspodcast #Podcast #LeyendasLegendarias Learn more about your ad choices. Visit megaphone.fm/adchoices

¿Estás listx para saciar tu sed de misterio? Toma tu pala, tu cinta aislante y tu cuchillo preferido, ¡porque en Leyendas Legendarias desenterramos a tus asesinos seriales favoritos! La historia de un productor musical que reclutaba niñas con la ayuda de una cantante. Les prometía llevarlas al éxito en la música, pero en realidad sólo las quería para abusar sexualmente de ellas. También puedes escucharnos en Spotify, Apple Podcasts, Amazon Music o tu app de podcasts favorita. Apóyanos en Patreon: https://www.patreon.com/leyendaspodcast Apóyanos en YouTube: https://www.youtube.com/c/leyendaslegendarias/join Visita nuestra página para ver contenido extra: www.leyendaslegendarias.com Síguenos: https://instagram.com/leyendaspodcast https://twitter.com/leyendaspodcast https://facebook.com/leyendaspodcast #Podcast #LeyendasLegendarias Learn more about your ad choices. Visit megaphone.fm/adchoices

Kendra Calhoun, Senior Vice President of Marketing, Communications & Digital Experience at Avera Health joins the podcast to share insights into her background & Avera Health, the biggest issues in healthcare she is keeping an eye on today, her excitement and nerves surrounding AI, and more.

Trivia Legendaria: Disponible para todo México en Amazon y Mercado Libre Amazon México: https://amzn.to/3NxeAOc Mercado Libre: https://bit.ly/3VNQ14v Amazon EUA: https://amzn.to/3syy8KJ Ivan Milat, conocido como el asesino de mochileros, perpetró una serie de crímenes brutales en Australia en la década de 1990. Sus acciones dejaron una huella sombría en la historia criminal del país y causaron conmoción en todo el mundo. También puedes escucharnos en Spotify, Apple Podcasts, Amazon Music o tu app de podcasts favorita. Apóyanos en Patreon: https://www.patreon.com/leyendaspodcast Apóyanos en YouTube: https://www.youtube.com/c/leyendaslegendarias/join Visita nuestra página para ver contenido extra: www.leyendaslegendarias.com Síguenos: https://instagram.com/leyendaspodcast https://twitter.com/leyendaspodcast https://facebook.com/leyendaspodcast #Podcast #LeyendasLegendarias Learn more about your ad choices. Visit megaphone.fm/adchoices

Trivia Legendaria: Disponible para todo México en Amazon y Mercado Libre Amazon México: https://amzn.to/3NxeAOc Mercado Libre: https://bit.ly/3VNQ14v Amazon EUA: https://amzn.to/3syy8KJ Ivan Milat, conocido como el asesino de mochileros, perpetró una serie de crímenes brutales en Australia en la década de 1990. Sus acciones dejaron una huella sombría en la historia criminal del país y causaron conmoción en todo el mundo. También puedes escucharnos en Spotify, Apple Podcasts, Amazon Music o tu app de podcasts favorita. Apóyanos en Patreon: https://www.patreon.com/leyendaspodcast Apóyanos en YouTube: https://www.youtube.com/c/leyendaslegendarias/join Visita nuestra página para ver contenido extra: www.leyendaslegendarias.com Síguenos: https://instagram.com/leyendaspodcast https://twitter.com/leyendaspodcast https://facebook.com/leyendaspodcast #Podcast #LeyendasLegendarias Learn more about your ad choices. Visit megaphone.fm/adchoices

Research is a key component of any health system. So, when it comes to serving rural areas, how do these systems reach patients and populations that may otherwise be left out of the research process?Valerie Schremp Hahn, Associate Editor of Catholic Health World, and Amy Elliott, PhD, the Avera Research Institute's Chief Clinical Research Officer, join Health Calls to discuss Hahn's recent article covering Elliott's work for Avera's mobile research lab. Elliott walks through the process of funding the lab, the challenges of operating it and how being on the road brings a wealth of opportunities to rural communities.

Los Amos del Universo: con Alexa Zuart y Nicho Peñavera / Situaciones random (Parte 1) Learn more about your ad choices. Visit megaphone.fm/adchoices

Los Amos del Universo: con Alexa Zuart y Nicho Peñavera / Situaciones random (Parte 2) Learn more about your ad choices. Visit megaphone.fm/adchoices

Los Amos del Universo: con Alexa Zuart y Nicho Peñavera / Situaciones random (Parte 3) Learn more about your ad choices. Visit megaphone.fm/adchoices

Los Amos del Universo: con Alexa Zuart y Nicho Peñavera / Situaciones random (Parte 4) Learn more about your ad choices. Visit megaphone.fm/adchoices

001 Yim Yim - Giants Nest 002 Rayana Jay - Nothin to Talk About 003 MF Doom - Doomsday feat. Pebbles The Invisible Girl 004 Meltt - Love Again 005 Mac DeMarco - Heart to Heart 006 Giyo - Downward Spiral 007 Beachy Head - Mechanical Me (Bonobo Mix) 008 Avera feat. Ellae - God Is A Woman 009 Crazy - Gnarls Barkley 010 Etro - Anime Diablo 011 Hugo Kant - In Time 012 Q Funktion - Since Then 013 Mr Cooper - Ten 014 Kinobe - Heartstring 015 Rali Ralev - Pure (feat. Morningstar) 016 Blackwave - Elusive feat. David Ngyah 017 Wax Tailor - Que Sera (Phonovisions Symphonic Version) 018 The Avalanches - Frontier Psychiatrist 019 Ayax y Prok - Reproches 020 Hugo Kant - Entering the Black Hole 021 Hugo Kant - So Why (Cuz Remix) 022 N.E.R.D. - Provider 023 Radiohead - Climbing Up The Walls (Zero 7 Mix) VS. Cristobal Tapia De Veer - Gifted (Pimped Mix) MASHUP

That's Right!! Welcome back to another exciting new episode with My Awesome Guest - DJ Avera!! Multi-Platform DJ Covering her beginnings as a DJ, Harmonic Mixing, Meeting w/clients before their events, Mixing w/ Controllers Vs Turntables! & Much More!! https://www.youtube.com/@averamusic https://instagram.com/djaveramusic?igshid=OGQ5ZDc2ODk2ZA== --- Send in a voice message: https://podcasters.spotify.com/pod/show/victor-ochoa89/message

Kiddushin without Avera follows the father

In the spring of 1982, 22-year-old Diana Avera was sent to Searcy Hospital, a mental health facility in southern Alabama. Diana was arrested for disorderly conduct in Foley, Alabama, where she lived. The details of her arrest are unknown because we only truly know what happened after her arrest. Diana had several mental health diagnoses, and the decision was made to send her to the mental health facility. Just three months later, around the beginning of August 1982, Diana allegedly escaped from the hospital and was never seen again. But is that really what happened 40 years ago in a case shrouded in secrets, abusive hospital practices, and unanswered questions? If you have any information about Diana's disappearance, please call the Mobile County Sheriff's Office at 251-581-1181.This episode was sponsored by:Hungryroot- Get 30% off your first delivery and free veggies for life at Hungryroot.com/VANISHED.Audible- Visit Audible.com/MIA or text MIA to 500-500 to try Audible free for 30 days.Factor- Head to FactorMeals.com/vanished50 to get 50% off.If you have a missing loved one that you would like to have featured on the show, please fill out our case submission form.Follow The Vanished on social media at:FacebookInstagramTwitterPatreonSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Drs. Pedro Barata and Naomi Haas discuss the emergence of clinical trials investigating triplet combinations in advanced renal cell carcinoma, factors that influence treatment decisions, strategies to personalize therapies in the frontline setting, including response-adaptive treatment strategies, and the use of biomarkers such as gene expression analysis to guide initial therapy. TRANSCRIPT Dr. Pedro Barata: Hello, I'm Dr. Pedro Barata. I'm your guest host of the ASCO Daily News Podcast today. I'm an associate professor of medicine and also a GU medical oncologist at University Hospital Seidman Cancer Center, Case Western University in Cleveland, Ohio. I'm also an associate editor for the ASCO Educational Book. Today I'm really delighted to welcome Dr. Naomi Haas, the director of the Prostate and Kidney Cancer Program at the Abramson Cancer Center and professor of medicine at the University of Pennsylvania.  Welcome, Dr. Haas. Dr. Naomi Haas: Thank you, Dr. Barata. It's a pleasure to be interviewed. Dr. Pedro Barata: Thank you. As you know, we've seen significant strides in the frontline treatment for patients with advanced clear cell renal cell carcinoma (RCC), and there are multiple doublet regimens that are now the standard of care for those patients. The goal for us to chat today is to discuss the emergence of clinical trials that are really investigating triple combinations and the factors that influence treatment decisions around triplet combinations for patients with advanced renal cell carcinoma. I want to congratulate you for the great work that you did in a recently published article in the 2023 ASCO Educational Book. So thank you for your contributions. And just before we get started, I just want to highlight that our full disclosures are available in the transcript of this episode. So, Dr. Haas, again, it's great to have you. Thank you for taking the time. Let me get started. So, we know that there are multiple standard of care doublet regimens, all of them immunotherapy-based combos, and they usually include 1 checkpoint inhibitor or 2, such as ipilimumab plus nivolumab or a combination of an immune checkpoint inhibitor with a VEGF TKI. And we have a number of examples like that. Can you tell us about the trials that have emerged exploring triplet therapies in the first-line setting for patients with advanced RCC? Dr. Naomi Haas: Sure, and I'm going to focus just on triplet therapies that are just about ready to go. But as you know, Pedro, there are probably many different combinations that we'll see in the future. Some of the combinations that have already been conducted as clinical trials include combinations of VEGF receptor tyrosine kinase inhibitors along with immune checkpoint inhibitors. I'll highlight one which was batiraxcept plus cabozantinib and nivolumab, and it's a combination of VEGF inhibitor, immune checkpoint inhibitor, and also an AXL inhibitor. So, most of these capitalize on other vulnerabilities with renal cell carcinoma.  So, as you said, they build on the tyrosine kinase inhibitor pathway or on the immune checkpoint inhibitor pathway. Some of them are combining drugs such as CDK inhibitors. There was axitinib plus nivolumab plus palbociclib trial that is getting ready to launch. Others are combining the use of belzutifan, which is a HIF inhibitor in combination with VEGF inhibitor and immune checkpoint inhibitor. There are a couple of those that are ongoing, one of them looking at combinations with lenvatinib. And I think there are also trials getting ready to launch that are using it in combination with cabozantinib and nivolumab.  Additionally, another very interesting direction is trying to affect the gut microbiome. And there was a clinical trial presented by Dr. Monty Pal at the gut microbiome session at ASCO, which combined CBM-588, which is a probiotic, in combination with cabozantinib and nivolumab. And that showed an improvement in progression-free survival compared to the combination of cabozantinib and nivolumab alone. And previously there was work published using CBM-588 in combination with ipilimumab and nivolumab. So that's an area of high interest to patients. But most of these combinations capitalize on either vulnerabilities, signs of resistance in pathways or in adding other pathways that have previously been unaddressed in renal cell carcinoma, and are combined with pathways that we know are effective. Dr. Pedro Barata: Wow, that's a fantastic overview of some of the approaches being considered in the frontline, so thank you for that. And actually to your point, some of them we've seen some data, others more later stages of development. So with that in mind, we also know that we have on one side of the story we have how much of these combos of triplets can actually be effective and help patients. From the other perspective is about tolerability, treatment options, and patient health. They're both very important considerations.  Can you tell us a little bit about the safety profile of these triplet combos? I know we're talking about many different things. The microbiome triplet has a different safety profile than perhaps a combination with a TKI and different checkpoints, for instance. Can you tell us a little bit about what we expect from the safety profile when we start to combine these therapies in the upfront setting?  Dr. Naomi Haas: Sure. I think 2 of the very tolerable triplet regimens have been the combination of the CBM-588 in combination with ipilimumab and nivolumab. Really in those combinations, the authors at least have demonstrated that there has not been a great difference between the two study arms of either the doublet or the doublet in combination with the CBM-588 trial. And that's based on basically changing the bacterial flora of the gut. The Avera trial, which was using the AXL inhibitor in combination with cabozantinib and nivolumab, also seems to have a very tolerable safety profile. Now, this trial was not compared to sort of a standard of care arm, so it's a little bit difficult. A standard of care arm that I would have considered for this clinical trial would have been to use either cabozantinib alone or cabozantinib with nivolumab. Instead, this was more of a dose-finding protocol. So, more work needs to be done with that, but the side effects of that combination additive to what we already know seem to be just infusion reactions from the AXL inhibitor.  The trial that got the most attention so far has been COSMIC-313, which was combining cabozantinib with ipilimumab and nivolumab upfront. And of course, the concern with this triplet combination was that there was more hepatotoxicity seen and it was difficult to know whether the hepatotoxicity was from the combinations of the immune checkpoint inhibitors or the use of the cabozantinib. And although the trial showed an improvement in progression-free survival, it did not show as many complete responses as the comparator arm. And the other concern was that there was quite a bit of dropout due to toxicity. And of course, we don't have the overall survival endpoint for that trial yet. Dr. Pedro Barata: Great, thank you for that. I agree completely. We've seen many different safety profiles with these different triplets.  Let me touch base on a slightly different topic, and that has to do with what kind of strategies can we think to personalize treatment for clear cell RCC in the frontline. And this is not necessarily applicable only to triplet therapy. There are also some efforts with doublets, but the goal is, I would argue, is response adaptive treatment strategies or even the use of upfront biomarkers such as gene expression analysis, for example, to help us guide initial therapy. Can you give us an idea what your thoughts are about what is coming? What do you think the future will look like in terms of developing this like a biomarker-based approach? What kind of factors or markers we can use to select who gets what in the frontline setting? Dr. Naomi Haas: Sure. So, I'll just highlight ahead of that that one important biomarker that we're already using is the IMDC criteria, which I think if that algorithm had not been developed, we would be struggling a lot in renal cancer and that's, of course, the algorithm that uses the thing such as performance status, hemoglobin, calcium, and time for the development of metastatic disease as well as the neutrophil count and the platelet count. And that has helped us divide categories of patients with clear cell renal cell carcinoma into poor risk, intermediate risk, or favorable risk categories. And that was recently validated in the immune therapy combinations that were previously been validated just in VEGF inhibitor therapies.  But the other useful, let's start with clinical tools that I think are going to be very important are the health-related quality of life tools which primarily measure things such as functional health, as well as toxicity. And one of these is the FKSI-19 score which captures most renal disease-related symptoms, treatments, side effects, and functional well-being. And this has been implemented in some trials and are looked at over time whether the patient's functional status improves. And patients who are responding to therapies generally will improve as far as their overall well-being. Although that can be difficult as a tool because if patients are experiencing toxicity, those signs might not be apparent. But that's one tool that's being used.  Now, people, both patient advocates and patients, have pointed out that it's very hard to use a tool like this in real life to implement in clinic, but there are efforts being carried out to make these tools a little bit easier so that people can use them day-to-day. So, I can see that being implemented more often.  The others have to do with response assessments, and I think it's very important to look at immune-related responses which kind of builds on the resist response, but it uses two dimensions of measurement as opposed to one dimension of measurement. And looking at those, we know now that patients who have what we call a deep response, so something better than a 75% shrinkage or even a 90% shrinkage in a very short period of time tend to be those patients who behave like patients who have complete responses. And both progression-free survival and overall survivals seem to be going in a very encouraging way looking at these tools so you could see that this tool could be implemented in real life with treating a patient and if they have a very deep response quickly, you can feel, the physician or the APP, could be very confident that the patient is going to do well for a long period of time. I think the tools that we're waiting for the most, however, are as you said, the biomarker tools. And this is where we still have a lot of work to do, but one example of this is the transcriptomics which has been conducted in both the atezolizumab-based trials such as the IMmotion trials, and also to some extent with the JAVELIN trials, the avelumab and axitinib trials. And this goes back to looking at the tissues sample and looking at transcriptomics which show mRNA expression as well as some alterations in some of the important genes such as BAP1 and PRBM1.  And those tools have been implemented, especially in the IMmotion trial, there were 7 clusters identified, and two of the clusters are groups of patients whose tumors have transcriptomics that indicate that they would respond well to a VEGF inhibitor. And a couple of them also showed very good responses to immune checkpoint pathways. There were additional pathways which suggested that patients wouldn't be responsive to either of these. And there is a trial called OPTIC that is funded by the Department of Defense (DOD) which is currently applying these transcriptomics, and then assigning patients to get either a VEGF IO therapy combination or a dual immune checkpoint inhibitor combination, based on their transcriptomics.  And I think what everybody would really like to see is, number 1, that these transcriptomics consistently bear out that there isn't irregularity in using these as predictors. So, they do need to be validated. But I think if there was a quick and easy way to do this, to assign patients to therapies based on these profiles, that would perhaps go a long way in predicting what therapy a patient should start with.  Another useful tool is the development of artificial intelligence. And there are a number of companies that are looking at these tools. We're implementing this retrospectively in the ASSURE trial, which was the adjuvant seraphinib synontib or placebo trial, for patients at high risk for RCC. And we're working with a company to identify, using AI, looking at the slides. And I think that if these kinds of techniques, which are already being used in prostate cancer, are something that can be developed, then what I could see in the future is that a patient's slide could be tested very quickly, and that that might also indicate things that perhaps we can't see under the microscope, as far as either a response to treatment or a risk. So, you could use that in the adjuvant setting to predict whether a patient might need adjuvant therapy or not. So I can see those being implemented.  And then the third is looking at cell-free DNA. And there are many different mechanisms that have been tested in other solid tumors, using either circulating tumor DNA or cell-free DNA. Now, the circulating tumor DNA seems to be a little bit more difficult to assess in metastatic kidney cancer because it doesn't have the mutational burden and doesn't seem to have as many mutations and things floating around that can be captured. However, cell-free DNA, which has the capability of measuring DNA methylation profiles, does seem to be showing some promise, and there have been some publications.  So this has also been tested in cancers of all stages and can be measured in both the plasma and in the urine. And that could be another helpful tool that needs to be validated, but that could be used to start a patient on treatment. And if the amounts of cell-free DNA went down with therapy, that could be a good indication, perhaps in advance of imaging, that a patient is doing well with therapy.  So those are some examples that I see potentially being used in the future to help direct therapy, provided that we can make these tools, that we can validate these tools, and secondly, that these tools are relatively inexpensive and that they're nimble, that they could be used right away, that it wouldn't take a long time to get the results back to help guide. Dr. Pedro Barata: For sure. I couldn't agree more. What a masterclass of all the emerging tools that are being investigated in RCC, this is fantastic.  So, I guess maybe one last question before I let you go. We have now a number of doublets, we have perhaps a triplet, if not more. If you were to guess, who do you think will be the ideal population for a triplet therapy? Some, in addition to all the tools you mentioned, maybe sarcomatoid features, etc. that might be part of the AI complement to what you mentioned earlier. But if you were to guess, do you think that 5 years from now, we're going to be offering a triplet therapy, whatever that triple therapy might be, to everybody, to certain populations? What can you tell us to help us predict what might happen in the near future to make us think about a thoughtful, shared decision-making process and try to predict who might be the ideal population for triplet therapy? Dr. Naomi Haas: So, I don't think we're going to use triplet therapy in everybody. And in fact, I hope we don't use triplet therapy in everybody because I have patients who have responded to single-agent nivolumab and remained in a continuous CR many years after they were treated that way. And I have other patients who really progressed very rapidly or relapsed very quickly after doublet therapy combinations. So, I think that what I would see in the future would be using the triplet therapy combinations in the challenging patients, the patients who we know we're not getting as far along with the doublet approach. And that's really our challenge. And I would see that perhaps some of this transcriptomics which indicates that there are subsets of renal cell carcinoma which are not going to respond well to a VEGF inhibitor or to an immune checkpoint inhibitor, that those are areas where there might be other relevant pathways where maybe the signal isn't quite as good with– maybe they have some response, but not an optimal response. And then combining another pathway into that would be a way forward to achieve a complete response in those populations.  I also want to emphasize that it may be that triplet therapy isn't the way to go, but that triplet therapy can be more of an adaptive design where a doublet therapy is started, and then the third drug, a triplet, is added at a later time. And an example of that is PDIGREE, which is the combination of ipilimumab and nivolumab. And then following imaging, patients are assigned, depending on the response, to get either cabozantinib alone, cabozantinib with nivolumab, or to continue on just nivolumab alone. And that might be a better way to address toxicity. But some of these other triplet combinations, one could also see- you could start, for example, with ipilimumab and nivolumab, and if they were having a response but you wanted to heighten the response, maybe adding the CBM-588 as an adaptive response or adding a CDK inhibitor, but sort of staggering the combination so that you spare patients some of the toxicity. So, I think all of those approaches need to be tested. Dr. Pedro Barata: That is fantastic. Dr. Haas, this is an incredible podcast. You did highlight several triplet combinations that are currently under investigation. You highlighted very, very important ongoing clinical trials. You touched base on what the future might bring as far as tools that might help us decide or optimize patient selection. We talked about adaptive designs. So really outstanding work. And also, I think this reflects the fantastic work in the manuscript that you wrote in the 2023 ASCO Educational Book.  So, thank you so much, Dr. Haas, for the incredible work that you have done and you continue to do in the GU field, and for taking the time to share your insights with us today on the ASCO Daily News Podcast. It's truly been a pleasure to chat with you today. Dr. Naomi Haas: Thank you.  Dr. Pedro Barata: Thank you again. And thank you also to our listeners for joining us today. Really happy with talking about this topic with Dr. Haas. You can also find links to the studies that we discussed today in the transcript of this episode. And finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcast.  So again, it has been a privilege to be here today with Dr. Haas. Thank you for joining us and have a good day.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Follow today's speakers:  Dr. Pedro Barata @PBarataMD Dr. Naomi Haas   Follow ASCO on social media:  @ASCO on Twitter  ASCO on Facebook  ASCO on LinkedIn    Disclosures:  Dr. Pedro Barata: Honoraria: UroToday Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Dendreon Speakers' Bureau (Inst): Caris Life Sciences, Bayer, Pfizer/Astellas Research Funding (Inst.):  Blueearth, AVEO, Pfizer, Merck   Dr. Naomi Haas: Consulting or Advisory Role: Pfizer, Merck Sharp & Dohme, Calithera, Eisai, Exelisis, AVEO, Roche/Genentech Expert Testimony: Lilly

Having the same mission as your partners makes impacting community SO much easier - and more fun! This is no better exemplified than by Journey Group's relationship with Avera Health. Join our conversation about how both of these organizations are positively impacting the lives of real people both individually and together through the building and renovating of Avera's care facilities. Hear from Garrett Peters, Vice President of Facilities at Avera, as well as our own Darin Hage, Aaron Eich, and Mark Lukonen as they discuss how our similar mission statements enable a smoother, safer, faster, and more impactful way of working together. That likemindedness generates trust and provides More than Construction to both our partners and our community!

Understanding Your Complete Blood Count: Hematologic Cancers | On Call with the Prairie Doc® | May 11, 2023 | Prairie Doc® host Dr. Andrew Ellsworth is joined by Dr. Xavier Andrade Gonzalez from Avera.

Hoy martes en La Caminera nos acompañó en una divertida entrevista Nicho Peñavera.

  Ian Avera | Episode # 297   Ian Avera is the new COO of the Big Air Kite League. We discuss how they plan to take BAKL to the next level, on and off the water.   Check out our new website:   http://portraitkite.com   Support the show:   https://ko-fi.com/megapod   Follow us:   http://www.kitesurf365.com   https://www.instagram.com/kitesurf365/   Contact:   megapodathotmail@gmail.com   Brought to you by:   TheKiteMag,  bringing you the very best in kiteboarding. Become a subscriber today and get 15% off by using the code “KITESURF365” at checkout.    https://www.thekitemag.com/    

El maestro Nicho Peñavera llegó, crudo, pero llegó porque el chisme puede más! Hoy presentamos: El tatuaje de la maestra + La despedida de la amante.   Así que acomódense en el sillón ✨, prepárense unas palomitas

Since the onset of the COVID 19 pandemic in March 2020, our nation's hospitals have paid a significant financial toll … and psychiatric hospitals are no exception.  Inpatient psychiatric admissions declined heavily throughout the pandemic. And while health professional shortages have long impeded behavioral health care access, the recent and forthcoming retirements of more than half of the current workforce, due in part to the COVID pandemic, only adds to provider challenges. In this podcast, Jordan Steiger, senior program manager, Behavioral Health, Clinical Affairs and Workforce at the AHA, speaks with Matthew Stanley, clinical vice president, Behavioral Health Service Line, with Avera Health, Sioux Falls, SD Like many hospitals and health systems, Avera Health continues to face significant challenges as expenses continue to escalate, patient boarding in emergency departments grows, and staffing shortages, often addressed by hiring expensive travel nurses as a solution, combine to create unsustainable budget pressures. Undeterred, Dr. Stanley and his team have accelerated their work to improve access to behavioral health care in the face of these daunting obstacles.

Sermon Text: Matthew 6:7-13

Top headlines: District 518 asks parents for help combatting vaping at WMS, Nobles County and the city of Worthington both talk budgeting, Avera@Home started home health and hospice programs in 2021, WHS gymnastics and boys basketball previews. The Globe Minute is a product of Forum Communications, brought to you by reporters at The Globe. For more news from throughout the day, check out dglobe.com.

En este nuevo episodio vamos a Japón este Tanuki es indispensable para agregar al Bestiario con el Conde Fabregat y Nicho Peñavera de invitado. Hosted on Acast. See acast.com/privacy for more information.

This week we're replaying a classic episode where your hosts Steve Lowry and Yvonne Godfrey interview Mark Avera of Avera and Smith (https://www.avera.com/).   Remember to rate and review GTP in iTunes: Click Here to Rate and Review   Episode Details: Gainesville, Florida trial lawyer Mark Avera of Avera & Smith explains how he secured justice for Yvonne Wiederhold, the wife of the late Rich Wiederhold, by connecting the actions of one negligent delivery driver in Orlando, Florida to the larger Domino's Pizza corporation through established right-of-control practices. Rich, a retired Brevard County District Fire Chief, strategically swerved and ultimately rolled his truck to avoid crashing into a Domino's delivery car that pulled out in front of him. Rich was rendered a quadriplegic and died 15 months later due to complications. An Orange County, Florida jury returned a verdict of $8,977,788.55 in damages against Domino's Pizza LLC. View/Download Trial Documents   Guest Bio: Mark Avera Like his father before him, Mark Avera has a history of many years of service to the people of Florida. His knowledge and understanding of the legal needs of his clients come not only from the practice of law but from his early career as sheriff's deputy in Alachua County. Before becoming a law partner at Avera & Smith in 1989 (then Avera & Avera), Mark served as a sheriff's deputy for Alachua County. He became the department's youngest deputy ever to be promoted to the rank of Sergeant. His primary assignments were uniform patrol division, SWAT, and the supervision of the department's Street Crimes Unit. Mark completed his bachelor's degree at the University of Florida while working midnight shifts for the Sheriff's Department and went on to graduate from UF with a law degree. Today, Mark serves as Managing Partner for Avera & Smith and works alongside his brother, Lance Avera, who specializes in workers' compensation law, and partner Rod Smith, who specializes in personal injury law. Mark is Board Certified in Civil Trial Law (B.C.S.) by the Florida Bar. He received his initial certification in 1998 and has remained qualified for board certification in civil trial law since that time. Board Certification is the Florida Bar's highest level of evaluation in competence and experience within a specific area of law and indicates superior professionalism and ethics in practice. Only slightly more than 1,000 of the more than 100,000 lawyers currently licensed in the State of Florida are actually Board Certified in Civil Trial Law. During his career, Mark's professionalism and dedication to his work as a trial advocate are reflected by his induction into the American Board of Trial Advocates (ABOTA) and in 2015 his induction into the International Society of Barristers. His accomplishments in the courtroom are recognized yearly in legal publications such as Florida Trend's Legal Elite, Florida's Super Lawyers, and in 2007 he was recognized by Lawdragon as one of the top 500 Plaintiff's lawyers in America. After the landmark Supreme Court decision in Engle v. Liggett Group, Inc., Mark has been involved in representing Engle plaintiffs against various tobacco companies responsible for the deaths of smokers who began smoking as children in the 1940s and 1950s. Beyond his professional achievements, he believes in community service to give back to the community which has been an integral part of his life. Mark serves on the Board of Directors for the Santa Fe College Foundation and in the past served on the Boards of Directors for the Children's Home Society, North Central Florida Community Foundation, and the Executive Committee of the North Florida Heart Ball, American Heart Association. Mark is married to the former Stacy Marie Upchurch and their blended family consists of four children; Alexandria, Danielle, Myles, and Weston. They all enjoy the outdoors and travel. Read Full Bio   Show Sponsors: Legal Technology Services - LegalTechService.com Digital Law Marketing - DigitalLawMarketing.com Harris Lowry Manton LLP - hlmlawfirm.com   Free Resources: Stages Of A Jury Trial - Part 1 Stages Of A Jury Trial - Part 2

"I was not supposed to be a drug addict, I was not supposed to be gay, I was not supposed to be someone who wanted to kill themselves." This was Nathan's thought as he considered suicide to repay his parents for all that he took from them. Instead, Nathan chose to live and this episode is his story. Nathan bravely shares his story of alcoholism, drug addiction, homosexuality, HIV diagnosis, and redemption. We recorded this episode on the day Nathan celebrated 21 months of freedom from drug addiction and 3 years of freedom from alcohol. Here are a few quotes that were highly impactful for us as we recorded: "I became whoever I needed to be for every situation." Speaking on his homosexuality: "No one wakes up asking for this. I was hardwired into this world." Praying: "Please don't make me be this way. I will live this perfect life if you will change this aspect of me." "I banked at the bank of Mom and Dad for a long time." "I had more confidence that the devil was real and that evil was real before I ever trusted God with my life...And that is a very scary place." "If the devil isn't after you then you really aren't living as a threat to him." "In the bottom of that bag was God." Resources: Suicide Hotline: 988 Helpline Center: www.helplinecenter.org Lost & Found: www.resilienttdoday.org Avera: www.avera.org/locations/profile/avera-addiction-care-center-sioux-falls/ KPP (Keep Pressing Play) Please consider sharing if this episode created ripples in your thought process. Instagram @mandatepod Email: mandate.pod@gmail.com Website: https://anchor.fm/mandate Patreon: https://www.patreon.com/mandatepodcast Sioux Falls Finest Sanitary Services Ben: ACE Garbage Service http://acegarbageservice.com/ 605.334.4223 or info@acegarbageservice.com Ryan: Novak Sanitary Services https://www.novaksanitary.com/ 605.338.7126 or Instagram @novaksiouxfalls --- Send in a voice message: https://anchor.fm/mandate/message

Dzenan Berberovic is the Chief Philanthropy Officer at Avera Health, an integrated health system located in Sioux Falls, South Dakota, and the surrounding areas. As a health ministry rooted in the Gospel, Avera's mission is to positively impact the lives and health of persons and communities by providing quality services guided by Christian values. Prior to his time with Avera Health, Dzenan was the Executive Director of Principal Giving for the University of South Dakota Foundation and the Chapter Consultant for the Pi Kappa Alpha International Fraternity. Dzenan held various roles at the University of South Dakota, where he received his bachelor's degree and then earned his MA in philanthropy and development from Saint Mary's University of Minnesota. In this episode… How can you communicate to donors in a way that emulates the challenges constituents face? What challenges did philanthropic teams encounter during the pandemic?  When the pandemic hit, philanthropic organizations needed to pivot and position themselves to continue their work. Dzenan Berberovic's heart and passion are in his work. With support from individuals and his positive attitude, his team continued providing crucial services to their constituents. How? Through employing a relationship model: reaching out to donors and having open communication.  In this episode of Cornerstone Unplugged, JP Cavaliere sits down with Dzenan Berberovic, Chief Philanthropy Officer at Avera Health, to talk about implementing conversations to raise contributions. Dzenan discusses how to support employees during difficult times, why gratitude must be the driving force behind organizations, and including behavioral health in campaigns.

Mental Health in Adolescents: Prevention, Signs and Resources, On Call with the Prairie Doc®, October 13, 2022. Host Dr. Debra Johnston with guests Dr. Nicole Chistensen from Avera Medical Group University Psychiatry Associates Sioux Falls and Curstie Konold, MPH from Avera outpatient services.

Healthcare leaders from Avera, Blue Shield of California, Renown Health and the Partners in Care Foundation discuss solving the last mile In healthcare, the link between the consumer and where care is delivered. When consumers can't pass through the last mile connection to the healthcare delivery system, they never even get an opportunity to engage with healthcare up close. Our panel will share success stories and best practices for improving access, creating a new business model and engaging consumers in their care. Panelists:  Mitchell Fong, Vice President of Virtual Care, Renown Health Daniel Rivas, Senior Manager, Community Health, Blue Shield of California Rhonda Weiring, Vice President, Clinical Innovation, Avera @Home Dianne Davis, Vice President, Community Wellness, Partners in Care Foundation   Bios: https://www.sharedpurposeconnect.com/events/novel-approaches-to-last-mile-care/   This episode of Bright Spots in Healthcare is sponsored by Partners in Care Foundation. The Partners in Care Foundation aligns social care and health care to address the “Social Determinants of Health” that routinely affect diverse, under-served, and vulnerable populations. PICF serves as a bridge between medical care and what individuals can accomplish on their own at home, achieving greater equity of conditions and effectiveness of care. Partners' evidence-based programs and services have been demonstrated to improve quality of life, help participants avoid suffering, and reduce costly hospital readmissions, Emergency Department visits, and nursing home placements.   For over two decades, the Partners in Care Foundation has been innovating and improving SDOH solutions and driving life-changing, life-saving alignment between social care and health care for those we serve. Please visit https://www.picf.org for more information.  

—— Conéctate con nosotros. Suscríbete a nuestro canal y activa la campana de notificaciones: https://bit.ly/lvryoutube Web: https://livingroomint.org Living Room Facebook: https://bit.ly/lvrfacebook Living Room Instagram: https://bit.ly/lvrinstagram Living Room Telegram: https://t.me/livingroomonline Carlos Fraija Instagram: https://bit.ly/carlosfraijainst #livingroomint #lvrtalks

“Feeling like they can't do enough for their patients, or that they're falling short with their patients, (that) they're disappointing their patients. And as you know, physicians can be very perfectionistic, want to fix things, and I often work with them on what are realistic expectations when you are in a rural setting.” -Mary Wolf, MS, LPC-MH, BCC Master Certified Coach Mary Wolf, president of Veritee Partners LLC, talks with cohost of the podcast Master Certified Coach Jill Farmer about the benefits and drawbacks of practicing medicine in rural settings. Oftentimes with fewer resources in smaller communities, there can be significant physician burnout in rural areas especially since the onset of COVID-19. How might physicians struggle to set boundaries in these communities where they often know their patients personally outside of the work office setting? Mary Wolf is able to offer valuable advice for physicians on how to set these boundaries between work and home so that they can practice medicine in a sustainable way.  Mary Wolf, MS, LPC-MH, BCC    Mary Wolf is the president of Veritee Partners LLC, a coaching and consulting business designed to promote wellbeing and success for physicians, executives, dentists, and the companies they serve.  Veritee Partners offers assessments and consultation for healthcare systems to build wellbeing programs and cultures.      Mary was the Program Director for the Avera Medical Group LIGHT Program, an award-winning wellbeing program for physicians and advanced practice providers. She led multi-strategy wellbeing services and provides executive coaching for physicians, nurse practitioners, physician assistants, residents, and executives.    Before creating LIGHT, Mary was the director of multiple behavioral health programs at Avera including employee assistance program-EAP, addiction recovery, outpatient mental health, and day hospital.    Mary earned a Master's Degree in Counseling and Human Resource Development and is a Licensed Professional Counselor-Mental Health. Mary is a Board Certified Coach and holds certifications in executive, life, and spirituality coaching.       Mary's extensive work with the Coalition for Physician Wellbeing includes being published as a chapter author for their two books:     Transforming the Heart of Practice:  An organizational and personal approach to physician wellbeing    Physician Well-being During Sustained Crisis:  Defusing Burnout, Building Resilience, Restoring Hope     Find full transcripts of DocWorking: The Whole Physician Podcast episodes on the DocWorking Blog  The past few weeks have been busy at DocWorking! We have been working behind the scenes to add even more CME credits to the THRIVE memberships.    Let your CME budget help you prioritize your own wellness so you can get on with living your best life on your own terms, as defined by you, with DocWorking THRIVE.   You can take the first step today by taking our 2 Minute Balance to Burnout Quiz! Where are you on the Balance to Burnout Continuum? Take the quiz and find out today!   DocWorking empowers physicians and entire health care teams to get on the path to achieving their dreams, both in and outside of work, with programs designed to help you maximize life with minimal time.   Are you a physician who would like to tell your story? Please email Amanda Taran, our producer, at podcast@docworking.com to be considered.   And if you like our podcast and would like to subscribe and leave us a 5 star review, we would be extremely grateful!   We're everywhere you like to get your podcasts! Apple iTunes, Spotify, iHeart Radio, Google, Pandora, Stitcher, PlayerFM, ListenNotes, Amazon, YouTube, Podbean   You can also find us on Instagram, Facebook, LinkedIn and Twitter.    Some links in our blogs and show notes are affiliate links, and purchases made via those links may result in payments to DocWorking. These help toward our production costs. Thank you for supporting DocWorking: The Whole Physician Podcast!   Occasionally, we discuss financial and legal topics. We are not financial or legal professionals. Please consult a licensed professional for financial or legal advice regarding your specific situation.   Podcast produced by: Mara Heppard

Boletos para la graduación de Bobby con Nicho en Cozumel 12 https://goliiive.com/nicho-penavera-show-de-graduacion ¡Escucha nuestra mini temporada exclusiva en Podimo! https://podimo.com/latam/herejes Apoya Herejes: https://www.patreon.com/herejeselpodcast Merch https://www.staymetal666.mitiendanube.com/ Ya vieron en su sin Libros: Nicho es uno de los comediantes más ácidos y veloces de la escena mexicana. Pero además, ha trabajado durante años en Marketing, y sabe muy bien como funcionan los mecanismos de esta industria de impulsar necesidades y embellecer productos. Entonces, los Herejes nos juntamos con el, para intentar entender como funciona la manipulación al consumidor, cuáles son sus límites. Y, sobretodo, como el Marketing se encuentra en muchas más situaciones diarias de las que pensamos. Una clase de engaños y trucos, para que todos estemos más atentos a los espejitos que compramos. -Nicho Peñavera - https://www.instagram.com/nichopenavera/ - https://www.youtube.com/c/NichoPe%C3%B1aVera - Ale Durán - https://twitter.com/FunkBob - - https://www.instagram.com/corsario.hereje/ - Ale Vázquez -  https://instagram.com/vasco.hereje/ - Bobby López - https://twitter.com/BobbyEsqvlz - https://www.instagram.com/bobby.hereje/ Fuentes: The History Of Marketing: From Trade to Tech - https://historycooperative.org/the-evolution-of-marketing-from-trade-to-tech Business Modelling: Why Selling Shovels During a Gold Rush is the Surest Way to Make Money https://medium.com/@transitprotocol/business-modelling-why-selling-shovels-during-a-gold-rush-is-the-surest-way-to-make-money-8fdf41f5bc1b Babies Means Business - https://newint.org/features/1982/04/01/babies/